Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 06 Feb 2018 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Mahindra Manulife Mid Cap Fund |
|---|---|
| 06 Feb 2018 | ₹100.00 |
| 24 Oct 2018 | ₹92.86 |
| 11 Jul 2019 | ₹97.65 |
| 26 Mar 2020 | ₹82.73 |
| 11 Dec 2020 | ₹120.41 |
| 28 Aug 2021 | ₹171.77 |
| 15 May 2022 | ₹165.68 |
| 29 Jan 2023 | ₹182.33 |
| 16 Oct 2023 | ₹245.47 |
| 02 Jul 2024 | ₹352.56 |
| 19 Mar 2025 | ₹320.87 |
| 03 Dec 2025 | ₹358.63 |
| 20 Aug 2026 | ₹398.92 |
| Metric | Mahindra Manulife · Regular NAV ₹37.28 Very High risk ★★★★☆ | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| +12.91% | +8.71% | |
| +20.61% | +18.06% | |
| +18.69% | +16.16% | |
| — | +15.69% | |
| +17.60% | +16.93% | |
| +18.70% | — | |
| +23.89% | +19.07% | |
| +23.29% | +16.56% | |
| — | +16.43% | |
| Risk | ||
| 16.90% | 16.23% | |
| 0.83 | 0.74 | |
| 1.12 | 1.00 | |
| -33.21% | -37.39% | |
| Nifty Midcap 150 | — | |
| +2.21% | +0.94% | |
| 0.94 | 0.94 | |
| 98.9% | 96.2% | |
| 88.3% | 90.1% | |
| 2.02% | 2.04% | |
| ₹4,747Cr | ₹7,594Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹1.00K | — | |
| 72% | 41% | |
| Manish Lodha · 5.7y | — | |
| 06 Feb 2018 | — | |
| 58 | — | |
| 26.0% | — | |
| 1.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.